Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Infections × gilteritinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 17 Targeted Therapy 1 Recurrence 1 Neoplasm, Residual 1 Myelodysplastic-Myeloproliferative Diseases 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid 1 Infections 1 Hematologic Neoplasms 1 Disease 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 8 Ciprofloxacin 6 Fluconazole 3 Daptomycin 3 Antibiotic Prophylaxis 3 gamma-Globulins 2 Voriconazole 2 Vancomycin 2 Trimethoprim 2 Sulfamethoxazole 2 Saline Solution 2 Ribavirin 2 Peripheral Blood Stem Cell Transplantation 2 Pentetic Acid 2 Melphalan 2 Itraconazole 2 Immunoglobulins, Intravenous 2 Fosfomycin 2 Ethanol 2 Cyclophosphamide 2 Cefazolin 2 Amoxicillin-Potassium Clavulanate Combination 2 ziprasidone 1 tocilizumab 1 telavancin 1 telaprevir 1 talquetamab 1 soybean oil, phospholipid emulsion 1 peginterferon alfa-2a 1 monalizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05791890 2023-03-30

GilteRInf

University of Rome Tor Vergata

Other hematologic neoplasm

Infections, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡